/ EN
HOME > NEWS&EVENTS

Undertaking to JHL for Voluntary Delisting from TPEx Emerging Stock Market

15 Jan 2018

Letter regarding Undertaking

Undertaking Form - Please print, sign and mail the completed form to JHL Biotech, Inc.

JHL Biotech Welcomes New Chief Medical Officer, Rong Chen

02 Jan 2018

JHL Biotech Welcomes New Chief Medical Officer, Rong Chen

JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

21 Dec 2017

JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

JHL Submits Clinical Trial Application for Proposed Bevacizumab Biosimilar

18 Dec 2017

 JHL Submits Clinical Trial Application for Proposed Bevacizumab Biosimilar

JHL Awarded top 20 Deloitte 2017 Asia Technology Fast 500 TM

13 Dec 2017

JHL Awarded top 20 Deloitte 2017 Asia Technology Fast 500 TM